Dynavax Technologies Corporation (DVAX) Announces Earnings Results, Beats Estimates By $0.15 EPS
Dynavax Technologies Corporation (NASDAQ:DVAX) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15, Bloomberg Earnings reports. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the previous year, the business earned ($0.90) EPS. Dynavax Technologies Corporation’s revenue was down 68.8% compared to the same quarter last year.
Dynavax Technologies Corporation (NASDAQ:DVAX) traded up $0.60 during trading on Friday, reaching $21.60. The company’s stock had a trading volume of 1,396,470 shares, compared to its average volume of 1,408,759.
A number of research analysts recently issued reports on the company. Cowen and Company restated a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Friday. Royal Bank Of Canada restated an “outperform” rating and set a $28.00 price target (up previously from $26.00) on shares of Dynavax Technologies Corporation in a report on Monday, September 25th. Cantor Fitzgerald started coverage on Dynavax Technologies Corporation in a report on Friday, September 15th. They set an “overweight” rating and a $24.00 price target on the stock. ValuEngine raised Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Finally, William Blair reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Dynavax Technologies Corporation currently has a consensus rating of “Buy” and an average target price of $25.00.
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.